Regorafenib-resistant PDGFR mutants

Stable Identifier
R-HSA-9674403
Type
Pathway
Species
Homo sapiens
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
Regorafenib-resistant PDGFR mutants
Click the image above or here to open this pathway in the Pathway Browser
Regorafenib is a type II TKI that is approved for the treatment of advanced gastrointestinal stromal tumors. Although regorafenib is effective against a number of KIT and PDGFR mutations, it only weakly inhibits the activity of the most prevalent PDGFRA allele, D842V (Evans et al, 2017).
Literature References
PubMed ID Title Journal Year
29093181 A precision therapy against cancers driven by KIT/PDGFRA mutations

Heinrich, MC, Zhang, Y, Hodous, BL, Shutes, A, Lengauer, C, Evans, EK, Kohl, N, Wolf, B, Schöffski, P, Zhu, XJ, Kim, JL, Gebreyohannes, YK, Gardino, AK, Wozniak, A, DiPietro, L, Lydon, N, Wilson, K, Brooijmans, N, Schmidt-Kittler, O, Boral, A, Miller, S, LaBranche, TP, Deangelo, DJ, Davis, A, Guzi, T, Wilson, D

Sci Transl Med 2017
Participants
Events
Participates
as an event of
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Rothfels, K  (2020-02-25)
Reviewed
Ip, CKM  (2020-02-06)
Created
Rothfels, K  (2020-01-13)
Cite Us!